
Keywords: aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid; APLAS, antiphospholipid antibody syndrome; AT1-AA, agonistic autoantibodies to the angiotensin II type 1 receptor; CH50, complement hemolytic activity; C1-INH, C1 esterase inhibitor; CR1, co